DelveInsight launched a new report on Postpartum Depression Market Insights, Epidemiology and Market Forecast-2030
DelveInsight’s ‘Postpartum Depression Market Insights, Epidemiology and Market Forecast – 2030’ report delivers an in-depth understanding of the Postpartum Depression (PPD), historical and forecasted epidemiology as well as the Postpartum Depression (PPD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the report
Request for sample pages: https://www.delveinsight.com/sample-request/postpartum-depression-market
Key benefits of the report
Postpartum Depression market size in the 7MM was USD 138.75 Million in 2017
Postpartum depression (PPD) or postnatal depression is a mood disorder that can affect women after childbirth. Mothers with postpartum depression experience feelings of extreme sadness, anxiety, and exhaustion that may make it difficult for them to complete daily care activities for themselves or for others. It greatly affects parents after childbirth. However, the risk of developing PPD is high if the mother has bipolar disorder, difficulty breast-feeding, having problems in their marital relationship, financial problems, etc. Without treatment, postpartum depression can last for months or years. DelveInsight’s ‘Postpartum Depression (PPD) Market’ report delivers an in-depth understanding of the Postpartum Depression (PPD), historical and forecasted epidemiology as well as the Postpartum Depression (PPD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Antidepressant medications, cognitive-behavioural therapy (CBT), and interpersonal therapy are useful in the Postpartum Depression (PPD) treatment.
There is only one FDA approved drug, namely, Zulresso- a neuroactive steroid gamma-aminobutyric acid (GABA), a receptor-positive modulator indicated for the treatment of postpartum depression (PPD) in adults.
Drugs covered in the report:- Emerging Therapies . Zuranolone (SAGE-217): Sage Therapeutics . Ganaxolone (CCD-1042): Marinus Pharmaceuticals and many others
Marketed Drug . Zulresso (brexanolone): Sage Therapeutics and many others
Key Companies Covered:
Table of contents
1 Key Insights 2 Postpartum depression Market Overview at a Glance 3 Disease Background and Overview: Postpartum depression (PPD) 4 Postpartum Depression Epidemiology and Patient Population 5 Country-Wise Epidemiology of Postpartum Depression (PPD) 5.1 United States 5.2 EU5 Countries 5.3 Germany 5.4 France 5.5 Italy 5.6 Spain 5.7 United Kingdom 5.8 Japan 6 Postpartum Depression Treatment 7 Postpartum Depression Treatment Algorithm by American Family Physician (AFP) 8 Postpartum Depression Treatment Guidelines by Unicare 9 Postpartum Depression Treatment Guidelines by the National Institute for Health and Care Excellence (NICE) 10 Recognized Establishments 11 Unmet Needs 12 Postpartum Depression Marketed Profile 12.1 Zulresso (brexanolone): Sage Therapeutics 12.2 Postpartum Depression Emerging Drugs 12.3 Key Cross Competition 12.4 Zuranolone (SAGE-217): Sage Therapeutics 12.5 Ganaxolone (CCD-1042): Marinus Pharmaceuticals 13 Postpartum Depression: 7 Major Market Analysis 14 The United States Market Outlook 14.1 United States Market Size 14.1 Germany 14.2 France 14.3 Italy 14.4 Spain 14.5 United Kingdom 15 Japan: Market Outlook 16 KOL Reviews 17 Case Reports 18 Market Drivers 19 Market Barriers 20 SWOT Analysis 21 Appendix 22 DelveInsight Capabilities 23 Disclaimer 24 About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market